A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

* Participant must have received at least 2 doses of 360 mg risankizumab maintenance therapy every 8 weeks postpartum prior to start of participation in this study. * Participant is at least 5 weeks postpartum by Day 1. * Lactation is well established. The mother must be exclusively breastfeeding her infant (or not providing more than 1 supplemental bottle of formula/day) when enrolled in the study. * Diagnosis of crohn's disease (or ulcerative colitis upon approval of ulcerative colitis in the participants location) as established by the principal investigator

* Participants who have major surgery planned during the conduct of the study (e.g., hip replacement, aneurysm removal, stomach ligation) * Participants with the following chronic or active infections: \-- Active HBV or HCV infection, defined as: * HBV: HBs Ag positive (+) test or detected sensitivity on the HBV DNA PCR qualitative test for participants who are HBc Ab positive (+) (and for HBs Ab positive \[+\] participants where mandated by local requirements). * HCV: HCV RNA detectable in any subject with HCV Ab. * Are infected with HIV, defined as confirmed positive anti-HIV Ab test. Note: In case a screened participant has a confirmed positive HIV Ab test,. * Active tuberculosis * Active systemic infection/clinically important infection during the last 2 weeks prior to the Baseline Visit as assessed by the investigator * Participants who have any of the following medical diseases or conditions: * Recent (within past 6 months) cerebrovascular accident or myocardial infarction; * History of an organ transplant which requires continued immunosuppression; * Active or suspected malignancy or history of any malignancy within the last 5 years except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix.